Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Capricor Therapeutics (CAPR) over the last 16 years, with Dec 2024 value amounting to -$3.4 million.

  • Capricor Therapeutics' Net Cash Flow fell 106.47% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.9 million, marking a year-over-year decrease of 182.28%. This contributed to the annual value of -$3.4 million for FY2024, which is 166.93% down from last year.
  • As of FY2024, Capricor Therapeutics' Net Cash Flow stood at -$3.4 million, which was down 166.93% from $5.1 million recorded in FY2023.
  • Capricor Therapeutics' Net Cash Flow's 5-year high stood at $28.8 million during FY2020, with a 5-year trough of -$25.3 million in FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$3.4 million (2024), whereas its average is -$7.9 million.
  • Per our database at Business Quant, Capricor Therapeutics' Net Cash Flow spiked by 4,554.62% in 2020 and then slumped by 1,239.14% in 2022.
  • Over the past 5 years, Capricor Therapeutics' Net Cash Flow (Yearly) stood at $28.8 million in 2020, then tumbled by 92.28% to $2.2 million in 2021, then crashed by 1,239.14% to -$25.3 million in 2022, then surged by 120.14% to $5.1 million in 2023, then crashed by 166.93% to -$3.4 million in 2024.